Long-term aripiprazole in youth with developmental disabilities including autism

Journal of Mental Health Research in Intellectual Disabilities

Volumn 4, Issue 1, 2011, Pages 40-52

  Hellings, Jessica A ^a   Boehm, Danna ^b   Yeh, Hung Wen ^c   Butler, Merlin G ^a   Schroeder, Stephen R ^d  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Johnson County Mental Health   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

Adolescents; Aripiprazole; Autism; Children; Long term

Indexed keywords

EID: 79952498834     PISSN: 19315864     EISSN: 19315872     Source Type: Journal    
DOI: 10.1080/19315864.2010.542274     Document Type: Article

References (31)

1. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
2. Baker, R., Newcomer, J., Kaplita, S., Han, J., Mathew, S., Mankoski, R.,... Pikalov, A. (2009, June-July). Effects of aripiprazole on metabolic measures in pediatric and adolescent patients: A pooled analysis of placebo-controlled trials. Poster presented at 49th annual National Clinical Drug Evaluation Unit meeting, Hollywood, FL.
3. Bouchard, L., Rabasa-Lhoret, R., Faraj, M., Lavoie, M. E., Mill, J., Pérusse, L., & Vohl, M. C. (2010). Differential epigenomic and transcriptomic responses in subcutaneous adipose tissue between low and high responders to caloric restriction. American Journal of Clinical Nutrition, 91, 309-320.
4. Burris, K. D., Molski, T. F., Xu, C., Ryan, E., Tottori, K., Kikuchi, T.,... Molinoff, P. B. (2002). Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics, 302, 381-389.
5. Byerly, M. J., Marcus, R. N., Tran, Q. V., Eudicone, J. M., Whitehead, R., & Baker, R. A. (2009). Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: Analysis of a randomized, open-label study. Schizophrenia Research, 107, 218-222.
6. Chang, K. D., Nyilas, M., Aurang, B. S., van Beek, A., Jin, N., Marcus, R.,... Findling, R. L. (2007, October). Efficacy of aripiprazole in children (10-17 years old) with mania (study 240). Poster presented at American Academy of Child and Adolescent Psychiatry, Boston, MA.
7. Cooper, W. O., Arbogast, P. G., Ding, H., Hickson, G. B., Fuchs, D. C., & Ray, W. A. (2006). Trends in prescribing of antipsychotic medications for U.S. children. Ambulatory Pediatrics, 6(2), 79-83.
8. Correll, C. U., Manu, P., Olshansky, V., Napolitano, B., Kane, J. M., & Malhotra, A. K. (2009). Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. Journal of the American Medical Association, 302, 1765-1773.
9. Findling, R. L., Kusumakar, V., Daneman, D., Moshang, T., De Smedt, G., & Binder, C. (2003). Prolactin levels during long-term risperidone treatment in children and adolescents. Journal of Clinical Psychiatry, 64, 1362-1369.
10. Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S.,... Carson, W. H. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. American Journal of Psychiatry, 165, 1432-1441.
11. Ghaffari, M., Malone, R. P., Kahn, A., West, S. H., Delaney, M. A., Lawrence, T.,... Hardison, H. H. (2009, June-July). Obesity in children with autism spectrum disorders. Poster presented at National Clinical Drug Evaluation Unit 49th annual meeting, Hollywood, FL.
12. Guy, W. (1976). ECDEU assessment manual for psychopharmacology (Rev. ed.). U.S. Department of Health, Education, and Welfare Publication (ADM), 76-338. Rockville, MD: National Institute of Mental Health.
13. Hellings, J. A., Cardona, A., & Schroeder, S. R. (2010). Long-term safety and adverse events of risperidone in children, adolescents, and adults with MR/DD. Journal of Mental Health Research in Intellectual Disability, 3, 132-144.
14. Hellings, J. A., Cardona, A., Zarcone, J. R., Ward, S. M., & Schroeder, S. R. (2004). Long-term safety and adverse events of risperidone in children, adolescents and adults with MR/DD. Poster presented at National Clinical Drug Evaluation Unit (NCDEU) annual meeting, Phoenix, AZ.
15. Hellings, J. A., Zarcone, J. R., Crandall, K., Wallace, D., & Schroeder, S. R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229-238.
16. Hellings, J. A., Zarcone, J. R., Reese, R. M., Valdovinos, M. G., Marquis, J. G., Fleming, K. K., & Schroeder, S. R. (2006). A crossover study of risperidone in children, adolescents and adults with mental retardation. Journal of Autism and Developmental Disorders, 36, 401-411.
17. Malone, R. P., Gratz, S., Delaney, M. A., & Hyman, S. B. (2005). Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders. CNS Drugs, 19, 923-934.
18. Marcus, R. N., Owen, R., Kamen, L., Manos, G., McQuade, R. D., Carson, W. H., & Aman, G. (2009). A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110-1119.
19. Marder, S. R., Glynn, S. M., Wirshing, W. C., Wirshing, D. A., Ross, D., Widmark, C.,... Blair, K. E. (2003). Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. American Journal of Psychiatry, 160, 1405-1412.
20. Martin, A., Scahill, L., Anderson, G. M., Aman, M., Arnold, L. E., McCracken, J.,... Vitiello, B. (2004). Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. American Journal of Psychiatry, 161, 1125-1127.
21. McDougle, C. J., Stigler, K. A., & Posey, D. J. (2003). Treatment of aggression in children and adolescents with autism and conduct disorder. Journal of Clinical Psychiatry, 64(Suppl. 4), 16-25.
22. Owen, R., Sikich, L., Marcus, R. N., Corey-Lisle, P., Manos, G., McQuade, R. D.,... Findling, R. L. (2009). Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533-1540.
23. Parikh, M. S., Kolevzon, A., & Hollander, E. (2008). Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability. Journal of Child and Adolescent Psychopharmacology, 18, 157-178.
24. Posey, D. J., Stigler, K. A., Erickson, C. A., & McDougle, C. J. (2008). Antipsychotics in the treatment of autism. Journal of Clinical Investigation, 118(1), 6-14.
25. Potkin, S. G., Saha, A. R., Kujawa, M. J., Carson, W. H., Ali, M., Stock, E.,... Marder, S. R. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry, 60, 681-690.
26. Reynolds, G. P., Zhang, Z. J., & Zhang, X. B. (2002). Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet, 359, 2086-2087.
27. Sanford, M., & Keating, G. M. (2007). Aripiprazole in adolescents with schizophrenia. Paediatric Drugs, 9, 419-423.
28. Stigler, K. A., Posey, D. J., & McDougle, C. J. (2004). Aripiprazole for maladaptive behavior in pervasive development disorders. Journal of Child and Adolescent Psychopharmacology, 14, 455-463.
29. Valicenti-McDermott, M. R., & Demb, H. (2006). Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. Journal of Child and Adolescent Psychopharmacology, 16, 549-560.
30. Waade, R. B., Christensen, H., Rudberg, I., Refsum, H., & Hermann, M. (2009). Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Therapeutic Drug Monitoring, 31, 233-238.
31. Yokoi, F., Grunder, G., Biziere, K., Stephane, M., Dogan, A. S., Dannals, R. F.,... Wong, D. F. (2002). Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): A study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology, 27, 248-259.